CSIMarket
 


Zeo Scientifix Inc   (BPSR)
Other Ticker:  
 

Zeo Scientifix Inc 's Quick Ratio

BPSR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2023, Quick Ratio deteriorated to 0.3 above company average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Quick Ratio than Zeo Scientifix Inc in first quarter 2023. While Quick Ratio total ranking has improved so far during the I Quarter 2023 to 1751, from total ranking in the forth quarter 2023 at 2417.

Explain Quick Ratio?
How much Cash & cash equivalents BPSRīs has?
What are BPSRīs Current Liabilities?


BPSR Quick Ratio (Jan 31 2024)
I. Quarter
(Oct 31 2023)
IV. Quarter
(Jul 31 2023)
III. Quarter
(Apr 30 2023)
II. Quarter
(Jan 31 2023)
I. Quarter
Y / Y Current Liabilities Change 14.51 % -1.31 % -51.61 % -45.61 % -30.78 %
Y / Y Cash & cash equivalent Change -18.85 % -53.51 % 380.24 % 898.71 % 624.27 %
Quick Ratio MRQ 0.3 0.44 0.2 0.35 0.42
BPSR's Total Ranking # 1751 # 2417 # 3203 # 2747 # 2669
Seq. Current Liabilities Change -2.17 % 20.93 % 1.01 % -4.17 % -15.69 %
Seq. Cash & cash equivalent Change -33.14 % 166.68 % -43.06 % -20.07 % -61.7 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 66
Healthcare Sector # 388
Overall Market # 1751


Quick Ratio Statistics
High Average Low
1.88 0.2 0
(Jul 31 2013)   (Oct 31 2014)




Financial Statements
Zeo Scientifix Inc 's Current Liabilities $ 4 Millions Visit BPSR's Balance sheet
Zeo Scientifix Inc 's Cash & cash equivalent $ 1 Millions Visit BPSR's Balance sheet
Source of BPSR's Sales Visit BPSR's Sales by Geography


Cumulative Zeo Scientifix Inc 's Quick Ratio

BPSR's Quick Ratio for the trailling 12 Months

BPSR Quick Ratio

(Jan 31 2024)
I. Quarter
(Oct 31 2023)
IV. Quarter
(Jul 31 2023)
III. Quarter
(Apr 30 2023)
II. Quarter
(Jan 31 2023)
I. Quarter
Y / Y Current Liabilities TTM Growth 14.51 % -1.31 % -51.61 % -45.61 % -30.78 %
Y / Y Cash & cash equivalent TTM Growth -18.85 % -53.51 % 380.24 % 898.71 % 624.27 %
Quick Ratio TTM 0.33 0.36 0.5 0.37 0.27
Total Ranking TTM # 1330 # 3798 # 4047 # 4070 # 2753
Seq. Current Liabilities TTM Growth -2.17 % 20.93 % 1.01 % -4.17 % -15.69 %
Seq. Cash & cash equivalent TTM Growth -33.14 % 166.68 % -43.06 % -20.07 % -61.7 %


On the trailing twelve months basis Due to decrease in Current Liabilities in the I Quarter 2023 to $3.92 millions, cumulative Quick Ratio decreased to 0.33 above the BPSR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 59 other companies have achieved higher Quick Ratio than Zeo Scientifix Inc . While Quick Ratio overall ranking has improved so far to 1330, from total ranking during the twelve months ending forth quarter 2023 at 3798.

Explain Quick Ratio?
How much Cash & cash equivalents BPSRīs has?
What are BPSRīs Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 60
Healthcare Sector # 352
Within the Market # 1330


trailing twelve months Quick Ratio Statistics
High Average Low
0.5 0.11 0.02
(Jul 31 2023)   (Apr 30 2018)




Companies with similar Quick Ratio in the quarter ending Jan 31 2024, within Biotechnology & Pharmaceuticals Industry Quick RatioJan 31 2024 MRQ Cash & cash equivalentJan 31 2024 MRQ Current Liabilities
Valneva Se  0.79 $ 141.210  Millions$ 177.927  Millions
Elutia inc   0.63 $ 19.276  Millions$ 30.390  Millions
Champions Oncology Inc   0.61 $ 4.468  Millions$ 7.335  Millions
Amgen Inc   0.60 $ 10,944.000  Millions$ 18,392.000  Millions
Protalix Biotherapeutics inc   0.52 $ 23.634  Millions$ 45.530  Millions
Coeptis Therapeutics Holdings Inc   0.50 $ 1.469  Millions$ 2.951  Millions
Cel sci Corporation  0.48 $ 2.319  Millions$ 4.867  Millions
Vaxart Inc   0.36 $ 4.958  Millions$ 13.724  Millions
Coherus Biosciences inc   0.35 $ 117.748  Millions$ 331.771  Millions
Novavax inc  0.35 $ 578.929  Millions$ 1,635.138  Millions
Biocardia Inc  0.31 $ 1.103  Millions$ 3.608  Millions
Zeo Scientifix Inc   0.30 $ 1.179  Millions$ 3.923  Millions
Outlook Therapeutics Inc   0.23 $ 10.357  Millions$ 45.968  Millions
Calidi Biotherapeutics Inc   0.19 $ 1.949  Millions$ 10.232  Millions
Gilead Sciences Inc   0.16 $ 1,179.000  Millions$ 7,478.000  Millions
Kiromic Biopharma Inc   0.16 $ 3.204  Millions$ 20.378  Millions

Date modified: 2024-03-19T10:04:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com